English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 2 August 2023, 21:38 HKT/SGT
Share:
Kingworld Medicines Expects 1H Profit Increased By 35%-40%
Demonstrating Strong Business Performance and Competitive Strengths

HONG KONG, Aug 2, 2023 - (ACN Newswire) - Kingworld Medicines Group ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced a projected rise in profit for the first half of the fiscal year. Based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ending June 30, 2023, the Group anticipates a profit surge ranging from approximately 35% to 40% for the period, compared to the same period last year.

The Board attributes this profit increase to increased revenue and gross profit stemming from the distribution of imported branded pharmaceutical and healthcare products in China, with growth rates reaching approximately 30% to 35% and 15% to 20%, respectively. Additionally, the Group's share of profit from a joint venture saw a boost of approximately 55% to 60% compared to the same period last year. This surge is attributed to the market recovery after the COVID-19 pandemic control measures.

Kingworld Medicines is a company specializing in the distribution of imported branded pharmaceutical and healthcare products in China. The Group adeptly navigated post-pandemic market changes, propelling business expansion by leveraging its industry strengths.

Mr. Zhao Lisheng, Chairman of the Board of Kingworld Medicines Group, commented: "The Group's profit increase was mainly due to market recovery and the Group's employees' unremitting efforts, which adapted post-pandemic. The Group's strengths lie in its strong capabilities in distributing pharmaceutical and healthcare products and its acute insights into the market. Besides, the Group has achieved long-term steady growth by continuously improving efficiency and expanding its business."

Looking ahead, Kingworld Medicines Group will continue to focus on increasing market share, expanding business coverage, and improving efficiency to further enhance the company's profitability and market competitiveness.


Topic: Press release summary Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Shaping the Future of Technology with AI Everywhere Take Center Stage at the 13th Big CIO Show   
May 10, 2024 20:55 HKT/SGT
DOCOMO to Launch "NTT DOCOMO GLOBAL" for Global Expansion  
Friday, May 10, 2024 5:13:00 PM
Japan Energy Summit and Exhibition Hosts and Sponsors Demonstrate the Importance of Accelerating Decarbonisation  
May 10, 2024 16:04 HKT/SGT
Pertamina International Shipping (PIS) Welcomes 2 VLGC Tankers to Its Fleet, Takes Top-Tier Position in ASEAN LPG Transport  
May 10, 2024 16:00 HKT/SGT
Q2 Metals Announces Assay Results from Its 2024 Winter Drill Program at the Mia Lithium Property, James Bay Territory, Quebec, Canada  
May 10, 2024 15:09 HKT/SGT
Speculation Swirls: ESR (01821.HK) Progresses in Privatization Talks Led by Warburg Pincus  
May 10, 2024 11:26 HKT/SGT
Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku"  
Friday, May 10, 2024 11:20:00 AM
InfoComm Asia 2024 "Asia's International Pro AV Exhibition" Returns to Thailand  
May 10, 2024 10:30 HKT/SGT
BLUETTI Unlocks Special Mother's Day Offerings, Perfect Gift Ideas for Moms  
May 10, 2024 10:00 HKT/SGT
AGILON HEALTH (NYSE: AGL) INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Agilon Health Investors of a Class Action Lawsuit and May 20, 2024 Lead Plaintiff Deadline  
May 10, 2024 08:33 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575